GFAP and Alzheimer disease: According to the evidence discussed in the present review, we believe that enhancing the AT(N) matrix by introducing the ATI(N) system, with the addition of neuroinflammatory biomarkers denoted as “I” (CSF and blood “I” biomarkers), such as GFAP, might significantly improve, in combination with the other biomarkers and cognitive testing, both the early diagnosis of AD and the development of disease-modifying drugs in future AD clinical trials.